MarketPeel
Insider Trading Intelligence
KW

Keith Woods

TCRX
DIRECTOR · TSCAN THERAPEUTICS, INC. · CIK 0001996804
FILING MIX · LIFETIME90%/10%
BUYS
18
SELLS
2
TOTAL VALUE
$1.22M
COMPANIES
5
ACTIVE SINCE
Oct 2023
HOLDINGS NOW
729,049
AVG SELL PX
$45.31
TRADE KIND
SHOWING 20 / 20
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 7 pending
Forward-return performance of every backtestable P/S trade by Keith Woods, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%-1.39%-0.68%-0.71%-0.71%
14d2+50.00%-3.12%+1.33%-4.45%-4.45%
30d2+0.00%+3.50%+2.00%+1.50%+1.50%
60d2+100.00%-9.99%+0.59%-10.58%-10.58%
90d2(1 pending)+0.00%+13.19%-1.11%+14.29%+14.29%
180d2(2 pending)
1y2(2 pending)
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TCRX · 67,000 shares · as of May 20, 2026
016,75033,50050,25067,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 18 buys / 2 sellsCOVERAGE · 11 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
67,00067,000May 20, 2026May 22, 2026View →
SRRK
SCHOLAR ROCK HOLDING CORP
SALE
Chief Operating Officer
10,220$49.57$506.7K620,055Apr 16, 2026Apr 20, 2026View →
NGNE
NEUROGENE INC.
PURCHASEGRANT
Stock grant
12,05012,050Feb 20, 2026Feb 24, 2026View →
SRRK
SCHOLAR ROCK HOLDING CORP
PURCHASEGRANT
Stock grant
47,021630,275Feb 9, 2026Feb 11, 2026View →
SRRK
SCHOLAR ROCK HOLDING CORP
SALE
Chief Operating Officer
16,746$42.70$715.1K583,254Jan 13, 2026Jan 15, 2026View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
67,00067,000Jun 30, 2025Jul 2, 2025View →
NGNE
NEUROGENE INC.
PURCHASEGRANT
Stock grant
12,05012,050Jun 12, 2025Jun 16, 2026View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
1,5006,000Jun 9, 2025Jun 10, 2025View →
SRRK
SCHOLAR ROCK HOLDING CORP
PURCHASEGRANT
Stock grant
110,067110,067May 2, 2025May 6, 2025View →
SRRK
SCHOLAR ROCK HOLDING CORP
PURCHASEGRANT
Stock grant
100,000100,000Apr 27, 2025Apr 29, 2025View →
SRRK
SCHOLAR ROCK HOLDING CORP
PURCHASEGRANT
Stock grant
500,000600,000Apr 27, 2025Apr 29, 2025View →
NGNE
NEUROGENE INC.
PURCHASEGRANT
Stock grant
7,7007,700Jun 14, 2024Jun 16, 2026View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
23,94423,944Jun 13, 2024Jun 20, 2024View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
47,50047,500Jun 12, 2024Jun 14, 2024View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
45,000135,000Jun 10, 2024Jun 11, 2024View →
NGNE
NEUROGENE INC.
PURCHASEGRANT
Stock grant
15,40015,400Jan 16, 2024Jun 15, 2026View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
11,96011,960Dec 7, 2023Dec 12, 2023View →
RCKT
ROCKET PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
20,52220,522Dec 7, 2023Dec 12, 2023View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,50017,500Dec 6, 2023Dec 8, 2023View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
90,00090,000Oct 16, 2023Oct 18, 2023View →
Other insiders · TCRX
Loading peer insiders…
About this filer
CIK 0001996804
ROLE
Director
PRIMARY
TCRX
COMPANIES
5
ACTIVE SINCE
Oct 2023
MARKETPEEL · /INSIDER/0001996804DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback